Research Analysts’ Weekly Ratings Updates for Qiagen (QGEN)

Several analysts have recently updated their ratings and price targets for Qiagen (NASDAQ: QGEN):

  • 9/13/2018 – Qiagen was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 9/6/2018 – Qiagen had its “buy” rating reaffirmed by analysts at Barclays PLC. They now have a $43.00 price target on the stock.
  • 8/29/2018 – Qiagen was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 8/29/2018 – Qiagen had its “buy” rating reaffirmed by analysts at Commerzbank AG.
  • 8/18/2018 – Qiagen was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 8/7/2018 – Qiagen had its “buy” rating reaffirmed by analysts at Commerzbank AG.
  • 8/3/2018 – Qiagen was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “QIAGEN registered better-than-expected second-quarter results with strong growth across majority of the segments. We are upbeat about QuantiFERON-TB test maintaining a dynamic double-digit growth pace and the company being on track with its target for $300 million of annual sales by 2020. We look forward to QIAGEN’s partnership with SRL in Japan. QIAGEN´s companion diagnostic workflows will be implemented by SRL. The company also delivered a strong performance with respect to operating margin. Meanwhile, its commitment to return more to shareholders through increased repurchases reflects its solid cash position. On the flip side, the company announced a negative impact from the disposals of several product portfolios announced in the second half of 2017. Also, competitive landscape and strong reliance on collaborations remain major overhangs. Overall, the company outperformed its industry over the past six months.”
  • 8/3/2018 – Qiagen had its “buy” rating reaffirmed by analysts at Deutsche Bank AG.
  • 8/2/2018 – Qiagen had its price target raised by analysts at Bank of America Corp from $38.00 to $39.00. They now have a “neutral” rating on the stock.
  • 8/2/2018 – Qiagen had its price target raised by analysts at Citigroup Inc from $35.00 to $38.00. They now have a “neutral” rating on the stock.
  • 8/1/2018 – Qiagen had its price target raised by analysts at Morgan Stanley from $37.00 to $38.00. They now have an “overweight” rating on the stock.
  • 7/25/2018 – Qiagen had its “buy” rating reaffirmed by analysts at Commerzbank AG.

Shares of NASDAQ QGEN opened at $38.23 on Friday. Qiagen NV has a 12-month low of $30.20 and a 12-month high of $39.45. The company has a debt-to-equity ratio of 0.69, a quick ratio of 4.59 and a current ratio of 5.07.

Qiagen (NASDAQ:QGEN) last announced its quarterly earnings data on Tuesday, July 31st. The company reported $0.33 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.32 by $0.01. Qiagen had a net margin of 2.85% and a return on equity of 11.74%. The company had revenue of $377.20 million during the quarter, compared to analysts’ expectations of $376.89 million. equities analysts forecast that Qiagen NV will post 1.34 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Exane Asset Management grew its stake in Qiagen by 17.0% during the 2nd quarter. Exane Asset Management now owns 761,887 shares of the company’s stock valued at $29,296,000 after acquiring an additional 110,651 shares in the last quarter. Jane Street Group LLC grew its stake in Qiagen by 127.4% during the 2nd quarter. Jane Street Group LLC now owns 126,788 shares of the company’s stock valued at $4,585,000 after acquiring an additional 71,029 shares in the last quarter. Castleark Management LLC purchased a new stake in Qiagen during the 2nd quarter valued at about $6,147,000. Sandler Capital Management grew its stake in Qiagen by 113.7% during the 2nd quarter. Sandler Capital Management now owns 744,390 shares of the company’s stock valued at $26,917,000 after acquiring an additional 396,080 shares in the last quarter. Finally, Cubist Systematic Strategies LLC grew its stake in Qiagen by 66.1% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 32,797 shares of the company’s stock valued at $1,186,000 after acquiring an additional 13,048 shares in the last quarter. 62.23% of the stock is owned by institutional investors.

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.

Read More: Short Selling Stocks and Day Traders

Receive News & Ratings for Qiagen NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen NV and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply